Ultimovacs ASA (OSL:ULTI)
kr 7.45 -0.1 (-1.32%) Market Cap: 256.32 Mil Enterprise Value: 38.98 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 30/100

Ultimovacs ASA at Redeye Investor AW Transcript

Oct 20, 2022 / NTS GMT
Release Date Price: kr70.1 (-1.96%)
Kevin Sule
Redeye AB - Analyst

Now, it's time for Ultimovacs along with CEO Carlos de Sousa. Welcome.

Carlos de Sousa
Ultimovacs ASA - CEO

Okay. Thank you. Good evening, everybody. My name is Carlos de Sousa. Thank you for being here and listen to Ultimovacs.

Ultimovacs is a biotech company located in Oslo. And because we are publicly listed, I need to show you this slide. I'm sorry first that I cannot do it in Swedish, but after the -- all presentations, if there are any questions, I will be here to answer.

Let me tell you what we do as a company. We work with a new generation of cancer vaccines. Cancer vaccines are becoming now more visible and rising in importance, particularly because some of the versions of old cancer vaccines were used to produce the COVID vaccines. Also a very recent deal where Merck acquired the cancer vaccine part of Moderna. That's one of the COVID. So really raised the interest more and more for cancer vaccines.

We have several benefits as a cancer vaccine. One is we are what is called off-the-shelf

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot